GE Healthcare Life Sciences and Germfree are combining their expertise to develop a fully integrated, expandable manufacturing solution for manufacturing emerging biotherapeutics, including gene therapeutic products

Currently the cell and gene therapy market is predicted to increase at a compound annual growth rate of more than 36% in the during 2019-2025¹. With more than 700 cell and gene therapies currently in clinical trials, demand exceeds supply. The collaboration with Germfree represents a significant contribution to increase capacity and capability in the gene therapy market.

The manufacturing solution will feature a Germfree modular bioprocessing environment based on GE Healthcare’s proprietary design and equipped with FlexFactory, GE Healthcare’s integrated single-use biomanufacturing platform. This will be the latest addition to GE Healthcare’s KUBio prefabricated manufacturing facility offering. To date, four KUBio facilities and 63 FlexFactory platforms have been acquired by manufacturers of biopharmaceuticals.

Reference:

1 Bloomberg (August 2019) Global Cell and Gene Therapy Market to Reach $11.96 Billion by 2025